Ultragenyx Pharma (RARE) Misses Q4 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ultragenyx Reports Fourth Quarter 2015 and Full-Year 2015 Financial Results and Corporate Update
February 25, 2016 4:06 PM ESTNOVATO, Calif., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the fourth quarter and full-year ended December 31, 2015.
2015 was a transformative year for Ultragenyx in which we advanced our entire product portfolio providing new possibilities for the treatment of rare disease patients, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. In 2016, we expect to have many clinical, regulatory and business development updates as we... More
